Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dicerna Pharmaceuticals Inc.

www.dicerna.com

Latest From Dicerna Pharmaceuticals Inc.

2018’s Top Biopharma Deal-makers

Even though 2018 did not feature the big influx of biopharma M&A that was expected, there were still encouraging signs that major advancements and breakthroughs in the biotech industry attract buy-outs. Cancer-focused companies and oncology assets again drove volume in alliances and financing transactions.

Deals Market Intelligence

Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron

Sanofi and Regeneron terminate the immuno-oncology partnership signed in 2015, but will continue to collaborate on Libtayo. Biogen signs a pair of partnerships in CNS disorders, with C4 and Skyhawk, and more deals from the first day of the J.P. Morgan conference.

Business Strategies Commercial

Lilly Ready For More Risk When It Comes To Early Deals

Chief Scientific Officer Dan Skovronsky has remit over business development at Eli Lilly, and he said the company is looking to do more deals, including higher-risk early stage molecules and new modalities, during an investor briefing in New York Dec. 19. The company also provided 2019 financial forecasts.

Business Strategies Deals

Multinationals Eye Divesting Established Products In China Amid Fierce Competition, Shifting Focus

Farewell established products, hello innovative new drugs! As pricing pressures mount, more multinational companies including Lilly and Roche are switching their business focus in China, looking at product divestments and partnering with local firms.

China Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dicerna Pharmaceuticals Inc.
  • Senior Management
  • Douglas M Fambrough, III, PhD, Pres. & CEO
    Jack Green, CFO
    Bob D Brown, PhD, SVP, CSO
    James B Weissman, CBO
    Ralf Rosskamp, MD, CMO
  • Contact Info
  • Dicerna Pharmaceuticals Inc.
    Phone: (617) 621-8097
    87 Cambridge Park Dr.
    Cambridge, MA 02140
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register